Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESCUE-UC: Upadacitinib Strategy in Acute Severe Ulcerative Colitis
NCT06660693Phase 3Recruiting
- Sponsor
- McMaster University
- Start
- Apr 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of upadacitinib in ulcerative colitis (UC) (2 arms), sponsored by McMaster University. Primary endpoint: Treatment success of upadacitinib vs standard care at 16 weeks. Started Apr 2025; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06660693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660693.